Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Controlled, Parallel Arms Clinical Study on the Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen (CEA) Monoclonal Antibody, for Locally Advanced or Recurrent Rectal Cancer Patients Undergoing Curative Surgery

NCT04642924 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.

NCT NCT04642924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04642924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Controlled, Parallel Arms Clinical Study on the Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen (CEA) Monoclonal Antibody, for Locally Advanced or Recurrent Rectal Cancer Patients Undergoing Curative Surgery
Lead sponsor
Leiden University Medical Center
Phase
Phase 2/3
Overall status
Unknown status
Start date
October 22, 2019
Completion date
October 31, 2023
Enrollment
203 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer, recurrent rectal cancer